PBX3 Promotes Tumor Growth and Angiogenesis via Activation of AT1R/VEGFR2 Pathway in Papillary Thyroid Carcinoma

Table 1

Correlation of PBX3 expression with clinicopathologic characteristics in PTC patients.

Clinicopathologic characteristics		PBX3 expression (%)		value	value
		Low expression	High expression
Total	63	14	49
Gender				0.001	0.971
Male	20	4 (20.0)	16 (80.0)
Female	43	10 (23.3)	33 (76.7)
Age (years)				0.114	0.736
≤50	34	7 (20.6)	27 (79.4)
>50	29	7 (24.1)	22 (75.9)
Tumor size (cm)				3.375	0.066
≤1	27	9 (33.3)	18 (66.7)
>1	36	5 (13.9)	31 (86.1)
Histopathological grade				0.198	0.657
G1 + G2	37	7 (18.9)	30 (81.1)
G3	26	7 (26.9)	19 (73.1)
Lymphatic metastasis				4.673	0.031
Absent	29	10 (34.5)	19 (65.5)
Present	34	4 (11.8)	30 (88.2)
TMN stage				8.490	0.004
T1 + T2	28	11 (39.3)	17 (60.7)
T3 + T4	35	3 (8.6)	32 (91.4)